Mathematical and Computational Models in Tumor Immunology

The immune system is able to protect the host from tumor onset, and immune de- ficiencies are accompanied by an increased risk of cancer. Immunology is one of the fields in biology where the role of computational and mathematical modeling and analysis were recognized the earliest, beginning from 60s of the last century. We introduce the two most common meth- ods in simulating the competition among the immune system, cancers and tumor immunology strategies: differential equations and rule-based models. Several specific implementations are pre- sented, describing in details how they work and how they advance or contribute the field of tumor immunology.

[1]  D. McDermott.  Retracted: Immunotherapy of metastatic renal cell carcinoma , 2009, Cancer.

[2]  A. Neumann,et al.  Control of the immune response by a threshold automata model on a lattice , 1989 .

[3]  M. Wirth.  Immunotherapy for metastatic renal cell carcinoma. , 1993, The Urologic clinics of North America.

[4]  A. Smith,et al.  Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize the effect of precursor frequency. , 2000 .

[5]  Federica Cavallo,et al.  Are oncoantigens suitable targets for anti-tumour therapy? , 2007, Nature Reviews Cancer.

[6]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[7]  Federica Cavallo,et al.  2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.

[8]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[9]  Piero Musiani,et al.  Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine , 2004, Cancer Research.

[10]  Paul Manneville,et al.  Cellular Automata and Modeling of Complex Physical Systems , 1989 .

[11]  H. V. Van Poppel,et al.  Vaccine therapy in patients with renal cell carcinoma. , 2009, European urology.

[12]  Cécile Gouttefangeas,et al.  Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer , 2009, The Prostate.

[13]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[14]  Brigitta Stockinger,et al.  T Cell Regulation as a Side Effect of Homeostasis and Competition , 2003, The Journal of experimental medicine.

[15]  Massimo Bernaschi,et al.  ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization , 2008, Briefings Bioinform..

[16]  Massimo Bernaschi,et al.  ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale† , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[17]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[18]  K. Mozdzanowska,et al.  Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. , 1994, Journal of immunology.

[19]  P. Musiani,et al.  Antimetastatic activity of a preventive cancer vaccine. , 2007, Cancer research.

[20]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[21]  Philippa Marrack,et al.  Epitope dominance, competition and T cell affinity maturation. , 2003, Current opinion in immunology.

[22]  L. Nguyen,et al.  Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. , 2010, Immunology letters.

[23]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[24]  G. I. Bell,et al.  Mathematical Model of Clonal Selection and Antibody Production , 1970, Nature.

[25]  D. Stauffer,et al.  A unified discrete model of immune response. , 1990, Journal of theoretical biology.

[26]  G. I. Bell,et al.  Mathematical model of clonal selection and antibody production. , 1970, Journal of theoretical biology.

[27]  Rolf M. Zinkernagel,et al.  Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes , 1998, Nature.

[28]  A. Perelson,et al.  Influenza A virus infection kinetics: quantitative data and models , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[29]  A. Abbas,et al.  Comprar Cellular and Molecular Immunology | Shiv Pillai | 9781416031222 | Saunders , 2007 .

[30]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[31]  Franco Celada,et al.  Affinity maturation and hypermutation in a simulation of the humoral immune response , 1996, European journal of immunology.

[32]  C. Parish.  Cancer immunotherapy: The past, the present and the future , 2003, Immunology and cell biology.

[33]  Vasso Apostolopoulos,et al.  MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral , 1998, Nature Medicine.

[34]  Filippo Castiglione,et al.  Modeling and simulation of cancer immunoprevention vaccine , 2005, Bioinform..

[35]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[36]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[37]  Filippo Castiglione,et al.  Modelling vaccination schedules for a cancer immunoprevention vaccine , 2005, Immunome research.

[38]  Robert A. Gatenby,et al.  Analysis of tumor as an inverse problem provides a novel theoretical framework for understanding tumor biology and therapy , 2002, Appl. Math. Lett..

[39]  P. Rod Dunbar,et al.  Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1 , 2002, The Journal of Immunology.

[40]  H. Tajiri,et al.  Cancer Vaccine by Fusions of Dendritic and Cancer Cells , 2010, Clinical & developmental immunology.

[41]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[42]  Robert D. Cardiff,et al.  Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.

[43]  Stephen Wolfram,et al.  Theory and Applications of Cellular Automata , 1986 .

[44]  Massimo Bernaschi,et al.  Computational modeling of the immune response to tumor antigens , 2005 .

[45]  Federica Cavallo,et al.  Vaccines for tumour prevention , 2006, Nature Reviews Cancer.

[46]  Freda K. Stevenson,et al.  Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen1 , 2002, The Journal of Immunology.

[47]  H Atlan,et al.  Network regulation of autoimmunity: an automation model. , 1989, Journal of autoimmunity.

[48]  M Kaufman,et al.  Towards a logical analysis of the immune response. , 1985, Journal of theoretical biology.

[49]  James F. Lynch,et al.  A Logical Characterization of Individual-Based Models , 2008, 2008 23rd Annual IEEE Symposium on Logic in Computer Science.

[50]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[51]  Brigitta Stockinger,et al.  T cell regulation: a special job or everyone's responsibility? , 2001, Nature Immunology.

[52]  S. Kim-Schulze,et al.  Cytokine therapy for cancer. , 2007, Surgical oncology clinics of North America.

[53]  F. Pappalardo,et al.  Analysis of vaccine's schedules using models. , 2006, Cellular immunology.

[54]  P. Musiani,et al.  Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent1 , 2004, The Journal of Immunology.

[55]  Nicola Bellomo,et al.  From the mathematical kinetic, and stochastic game theory to modelling mutations, onset, progression and immune competition of cancer cells ✩ , 2008 .

[56]  Philippa Marrack,et al.  T cells down-modulate peptide-MHC complexes on APCs in vivo , 2002, Nature Immunology.

[57]  Francesco Pappalardo,et al.  Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.

[58]  G. Bocharov,et al.  Modelling the dynamics of LCMV infection in mice: conventional and exhaustive CTL responses. , 1998, Journal of theoretical biology.

[59]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[60]  G. Weisbuch,et al.  Immunology for physicists , 1997 .

[61]  L. B. Wilson,et al.  A CASE OF SUSPECTED RABIES WITH ISOLATION OF BACILLUS DIPHTHERIÆ FROM THE CENTRAL NERVOUS SYSTEM , 1899, The Journal of experimental medicine.

[62]  P. Musiani,et al.  Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. , 2004, Journal of immunology.

[63]  G L Asherson,et al.  The control of the immune response. , 1975, Annals of allergy.

[64]  Helen M. Byrne,et al.  A Multiple Scale Model for Tumor Growth , 2005, Multiscale Model. Simul..

[65]  Stephanie Forrest,et al.  Infect Recognize Destroy , 1996 .

[66]  E. Tüzel,et al.  Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? , 2009, Future oncology.

[67]  Dietrich Stauffer,et al.  Immunologically Motivated Simulations of Cellular Automata , 1992 .

[68]  J. Stears,et al.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 , 1997, Cancer Immunology, Immunotherapy.

[69]  F. Castiglione,et al.  Computational modeling of the immune response to tumor antigens: implications for vaccination , 2004, 2004 43rd IEEE Conference on Decision and Control (CDC) (IEEE Cat. No.04CH37601).

[70]  Filippo Castiglione,et al.  Vaccine protocols optimization: in silico experiences. , 2010, Biotechnology advances.

[71]  Carl T. Bergstrom,et al.  Models of CD8+ responses: 1. What is the antigen-independent proliferation program. , 2003, Journal of theoretical biology.

[72]  R. Henriksson,et al.  Immunotherapy of metastatic renal cell carcinoma , 1997 .

[73]  A. Perelson,et al.  Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection , 2009, Journal of Virology.

[74]  Louis G. Birta,et al.  Modelling and Simulation , 2013, Simulation Foundations, Methods and Applications.

[75]  M. Mézard,et al.  Spin Glass Theory and Beyond , 1987 .

[76]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[77]  Federica Cavallo,et al.  Vaccines and other immunological approaches for cancer immunoprevention. , 2011, Current drug targets.

[78]  Yoram Louzoun,et al.  The evolution of mathematical immunology , 2007, Immunological reviews.

[79]  J. Šterzl.  Factors Determining the Differentiation Pathways of Immunocompetent Cells , 1967 .

[80]  A. Denman.  Cellular and Molecular Immunology , 1992 .

[81]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.